February 10, 2016: Ono Pharmaceutical Press Release
February 10, 2016: Ono Pharmaceutical Press Release
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Ono Pharmaceutical Press Release
- February 10, 2016
- Reading time: 1 minute
Ono Pharmaceutical announced early termination of a Phase III clinical trial of Opdivo in platinum-resistant, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) due to demonstrated overall survival benefit in the control group.
For more information on this clinical trial, please refer to the following link:
http://www.clinicaltrials.jp/us…/search/directCteDetail.jsp…
Ono Pharmaceutical press release link:
https://www.ono.co.jp/jpnw/PDF/n16_0202_02.pdf
#Head and Neck Cancer
Breakthrough in Pancreatic Cancer Aggressiveness Identified! New Immune Enhancement Agent Supports Cancer Immunotherapy Kyoto University Launches iPS Cell Cancer Treatment!
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4